UPC revenueFY2025$17.86B
- FY YoY
- -22.4%
- 5Y CAGR
- +257.2%
UPC revenue was $17.86B for fiscal 2025 (ended Sep 30, 2025), down 22.4% from fiscal 2024. Compound annual growth was +257.2% over 5 years. It rose in 2 of the last 6 fiscal years.
Universe Pharmaceuticals Inc. (UPC) financials
For fiscal 2025 (ended Sep 30, 2025), Universe Pharmaceuticals Inc. reported $17.86B of revenue and -$3.67B of net income.
- Revenue, FY2025
- $17.86B
- Revenue growth, YoY
- -22.4%
- Net income, FY2025
- -$3.67B
- Net margin
- -20.6%
- Free cash flow, FY2025
- -$5.32B
- EPS, diluted, FY2025
- -$8.06
- Cash
- $33.59B
- P/S
- 0.00
- Market cap
- $7.8M
FY2019FY2025
FY2019FY2025
FY2019FY2025
UPC revenue and earnings growth
UPC net incomeFY2025-$3.67B
UPC net income was -$3.67B for fiscal 2025 (ended Sep 30, 2025), compared with -$8.73B in fiscal 2024.
UPC EPSFY2025-$8.06
UPC diluted EPS was -$8.06 for fiscal 2025 (ended Sep 30, 2025).
UPC free cash flowFY2025-$5.32B
UPC free cash flow was -$5.32B for fiscal 2025 (ended Sep 30, 2025), compared with -$9.72B in fiscal 2024.
Income statement
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $17.86B | $23.02B | $32.31B | $40.14M | $47.98M | $30.70M | $33.23M |
| Cost of revenue | $11.56B | $16.95B | $21.99B | $18.25M | $22.66M | $16.61M | $19.82M |
| Gross profit | $6.30B | $6.07B | $10.32B | $21.89M | $25.33M | $14.09M | $13.41M |
| Research and development | $671.76M | $3.03B | $4.86B | $7.64M | $5.47M | $583.1K | $618.4K |
| Selling, general and admin | $3.75B | $2.89B | $2.64B | $2.18M | $3.30M | $1.70M | $1.46M |
| Operating income | -$2.92B | -$8.02B | -$3.97B | -$7.02M | $13.59M | $10.25M | $9.75M |
| Interest expense | $289.38M | $304.52M | $190.18M | $162.4K | $101.6K | $123.8K | $129.3K |
| Pre-tax income | -$3.67B | -$8.12B | -$4.33B | -$7.09M | $13.68M | $10.10M | $9.65M |
| Income tax | - | $606.70M | $2.25B | $815.3K | $2.36M | $2.54M | $2.10M |
| Net income | -$3.67B | -$8.73B | -$6.58B | -$7.91M | $11.32M | $7.56M | $7.55M |
| EPS, basic | -$8.06 | -$626.96 | -$1089.21 | -$1309.11 | $3.58 | $2.82 | $2.82 |
| EPS, diluted | -$8.06 | -$626.96 | -$1089.21 | -$1309.11 | $3.58 | $2.82 | $2.82 |
| Diluted shares | 455,871 | 13,920 | 6,042 | 6,042 | 3.2M | 2.7M | 2.7M |
Balance sheet
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $33.59B | $29.50B | $5.29B | $5.71B | $8.08M | $10.06M | $3.18M |
| Short-term investments | - | - | $13.22M | $13.15M | $13.73M | - | - |
| Receivables | $13.01B | $12.91B | $11.01M | $15.18M | $15.57M | $10.87M | - |
| Inventory | $2.19B | $1.74B | $3.34M | $2.21M | $2.46M | $1.91M | - |
| Current assets | $53.60B | $51.64B | $25.27M | $41.51M | $50.48M | $23.28M | - |
| Total assets | $69.30B | $67.95B | $41.72M | $59.54M | $70.14M | $28.80M | - |
| Current liabilities | $13.17B | $20.31B | $13.75M | $13.10M | $11.21M | $8.00M | - |
| Short-term debt | $2.11B | $5.86B | $5.48M | $3.94M | $4.33M | $2.65M | - |
| Total liabilities | $13.17B | $22.45B | $13.75M | - | - | - | - |
| Shareholders' equity | $56.13B | $45.50B | $27.97B | $35.33B | $46.99M | $20.80M | $12.38M |
Cash flow
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.05B | -$9.51B | $1.12B | -$1.30M | -$2.06M | $6.12M | $13.20M |
| Capital expenditures | $266.77M | $208.32M | $44.17M | $93.7K | $444.5K | $51.8K | $86.3K |
| Free cash flow | -$5.32B | -$9.72B | $1.07B | -$1.40M | -$2.50M | $6.06M | $13.12M |
| Investing cash flow | -$341.81M | -$361.29M | -$44.17M | -$3.91M | -$27.06M | -$51.8K | -$86.0K |
| Financing cash flow | $9.73B | $33.95B | -$1.39B | $3.32M | $26.58M | $470.1K | -$16.00M |
| Dividends paid | - | - | - | - | - | - | $16.00M |
| Depreciation and amortization | $517.43M | $485.73M | $508.79M | $533.9K | $446.9K | $410.1K | $418.4K |
Key ratios
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -22.4% | -28.7% | 80383.8% | -16.3% | 56.3% | -7.6% | - |
| Net income growth, YoY | - | - | - | - | 49.8% | 0.1% | - |
| EPS growth, YoY | - | - | - | - | 27.0% | 0.0% | - |
| Gross margin | 35.3% | 26.4% | 31.9% | 54.5% | 52.8% | 45.9% | 40.3% |
| Operating margin | -16.3% | -34.8% | -12.3% | -17.5% | 28.3% | 33.4% | 29.4% |
| Net margin | -20.6% | -37.9% | -20.4% | -19.7% | 23.6% | 24.6% | 22.7% |
| Free cash flow margin | -29.8% | -42.2% | 3.3% | -3.5% | -5.2% | 19.7% | 39.5% |
| Return on equity | -6.5% | -19.2% | -23.5% | -0.0% | 24.1% | 36.3% | 61.0% |
| Return on assets | -5.3% | -12.8% | -15772.6% | -13.3% | 16.1% | 26.2% | - |
| Current ratio | 4.07 | 2.54 | 1.84 | 3.17 | 4.50 | 2.91 | - |
Source: XBRL data Universe Pharmaceuticals Inc. files with the SEC, latest filing dated Jan 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-6, first reported Jan 30, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
UPC peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| UPC | $17.86B | -22.4% | -$3.67B | -20.6% | $7.8M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
UPC FAQ
9 questionsWhat is UPC revenue?
Universe Pharmaceuticals Inc. (UPC) reported $17.86B of revenue for fiscal 2025 (ended Sep 30, 2025). That is down 22.4% from the year before.Is UPC profitable?
No. Universe Pharmaceuticals Inc. reported a net loss of $3.67B for fiscal 2025 (ended Sep 30, 2025).How much cash and debt does UPC have?
Universe Pharmaceuticals Inc. reported $33.59B in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is UPC revenue growing?
Universe Pharmaceuticals Inc.'s revenue changed -22.4% in fiscal 2025, to $17.86B. Its compound annual growth rate was +257.2% over 5 years.What is UPC gross margin?
Universe Pharmaceuticals Inc.'s gross profit was $6.30B on $17.86B of revenue for fiscal 2025 (ended Sep 30, 2025), a gross margin of 35.3%.What is UPC free cash flow?
Universe Pharmaceuticals Inc. generated -$5.32B of free cash flow for fiscal 2025 (ended Sep 30, 2025), which is operating cash flow of -$5.05B less capital expenditures.What is UPC earnings per share?
Diluted earnings per share were -$8.06 for fiscal 2025 (ended Sep 30, 2025), from SEC filings, restated for any stock split those filings show.When did UPC last report financial results?
The latest statements here come from Universe Pharmaceuticals Inc.'s 20-F filed on Jan 29, 2026, covering the period ended Sep 30, 2025.Where does this UPC financial data come from?
Quantisnow builds these statements from the structured XBRL data Universe Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.